Compare iShares MSCI Japan ETF (EWJ) vs Cassava Sciences Inc (FLNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Japan ETF vs Cassava Sciences Inc — how do they compare? iShares MSCI Japan ETF trades at $97.08, while Cassava Sciences Inc trades at $0.97 (market cap $47.75M). The key difference: iShares MSCI Japan ETF is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| EWJ | FLNA | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $96.97 | $4.64 |
52-Week Low | $77.93 | $0.87 |
Market Cap | — | $47.75M |
Enterprise Value | — | -$34.93M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWJ, the iShares MSCI Japan ETF, trades at $96.90, up 1.84% with a bullish technical signal from moving averages. Recent U.S.-Japan yen intervention and domestic economic stimulus efforts, including a food tax cut, are key drivers. The ETF's RSI_6 at 90.64 indicates overbought conditions, while support and resistance cluster near $96-$97.
Outlook is cautiously optimistic due to policy support and export benefits from yen strength, but risks include inflation pressures and tech sector volatility. The dividend of $0.50 scheduled for June 2026 adds income appeal, though current financial ratios are undisclosed, requiring scrutiny of underlying holdings.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares MSCI Japan ETF
EWJ tracks the MSCI Japan Index, providing broad exposure to over 180 large and mid-cap companies in Japan. It is the most established and liquid vehicle for accessing the Japanese equity market, featuring a diversified portfolio across industrials, consumer discretionary, and financial sectors.
Read more on EWJ →About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →
